Stage 4 Mesothelioma: Symptoms, Treatment & Prognosis

Stage 4 diffuse pleural mesothelioma is defined by the presence of distant metastatic disease (M1). According to the AJCC/UICC TNM Version 9 staging system, pleural mesothelioma is classified as Stage IV when distant metastasis is present, regardless of the primary tumor or regional lymph-node category:

Any T, Any N, M1

This distinction is important. Stage 4 is not defined solely by a large pleural tumor, extensive chest-wall invasion, or regional lymph-node involvement. A T4 tumor remains Stage IIIB if distant metastasis is absent and the disease is M0.

Stage 4 is advanced disease and is generally not curable with current standard therapies. However, treatment continues. Systemic therapy, symptom management procedures, selected radiation therapy, clinical trials, and palliative care remain important. ASCO recommends systemic treatment for eligible patients, as it can improve survival and quality of life.

Stage 4 Mesothelioma at a Glance

What Does Stage 4 Mesothelioma Mean?

Pleural mesothelioma staging uses three components:

• T — Tumor: the extent of the primary pleural tumor.
• N — Nodes: whether regional lymph nodes contain mesothelioma.
• M — Metastasis: whether the cancer has spread to distant sites.

In Stage IV, the defining component is M1.

A patient can therefore have different T and N categories and still have Stage IV disease as long as distant metastatic disease has been identified.

The official Version 9 stage grouping is:

Stage IV = Any T + Any N + M1

This means the primary tumor does not have to be T4, and extensive regional nodal disease is not required.

AJCC Version 9: Any T, Any N, M1

Version 9 more clearly distinguishes advanced locoregional disease from distant metastatic disease than many simplified online explanations.

For example:

Stage IIIB
T4, Any N, M0

versus:

Stage IV
Any T, Any N, M1

A T4 tumor may invade major structures such as mediastinal organs, ribs, diaphragm, or pericardium, and may extend to the contralateral pleura. Without distant metastasis, it remains M0 and is classified as Stage IIIB.

Stage IV requires distant metastasis.

Therefore, statements like “Stage 4 means the tumor has grown very far in the chest” are incomplete. Local tumor extent and distant metastasis are separate components of TNM staging.

What Does M1 Mean?

M1 means distant metastatic disease has been identified.

Metastatic disease occurs when mesothelioma cells spread to sites distant from the primary pleural tumor.

Examples of distant involvement described in current patient-facing staging resources include sites such as:

• bone;
• liver;
• peritoneum;
• distant lymph nodes;
• the opposite lung or pleural region when involvement represents distant metastatic spread rather than direct contiguous extension;
• other distant organs or tissues.

An Important Contralateral Pleura Distinction

This distinction requires careful attention.

Under TNM Version 9, direct extension of the primary tumor to the contralateral pleura is a T4 feature. If there is no distant metastasis, T4 Any N M0 is Stage IIIB.

By contrast, separate metastatic involvement of the opposite lung or pleural region can represent distant disease and therefore M1. Current ACS staging information lists distant spread to the opposite lung or pleura among examples of Stage IV disease.

Imaging findings on the opposite side of the chest require clinical interpretation and should not be automatically labeled as Stage IV. ASCO notes that further evaluation may be appropriate when contralateral pleural abnormalities are found and the distinction could affect treatment planning.

Where Can Stage 4 Mesothelioma Spread?

Distant metastatic pleural mesothelioma can involve several sites. Current authoritative patient resources describe metastatic disease involving areas such as the peritoneum, bones, liver, the opposite lung or pleural region, distant lymph nodes, and other organs.

Metastatic patterns vary among patients.

Some patients have limited distant metastases, while others have more widespread disease. The Stage IV label alone does not reflect total disease burden.

Metastasis location also influences symptoms and treatment decisions.

Stage 3 vs Stage 4 Mesothelioma

The most important difference is M status.

Version 9 places T4 Any N M0 in Stage IIIB, while any T/any N with M1 is Stage IV.

A patient can therefore have very extensive local Stage IIIB disease without distant metastasis. In contrast, another patient with a less extensive primary tumor can be Stage IV because an M1 metastasis has been identified. See our Stage 3 mesothelioma guide for more detail.

Symptoms of Stage 4 Mesothelioma

No specific symptom pattern can diagnose Stage 4 mesothelioma or reliably distinguish it from other stages.

Possible symptoms of pleural mesothelioma include:

• shortness of breath;
• chest or rib-area pain;
• cough;
• fatigue;
• reduced exercise tolerance;
• pleural fluid accumulation;
• reduced appetite;
• unintended weight loss.

In Stage IV disease, additional symptoms may occur depending on where metastatic disease is located, but symptoms alone cannot establish M1 status.

A patient with extensive pleural fluid can be very breathless even without widespread metastatic disease, while another patient with Stage IV disease may initially have comparatively modest symptoms.

Stage is determined by clinical evaluation, pathology, and imaging, not by symptom severity. Our symptoms guide covers the broader range of possible signs across all stages.

How Is Stage 4 Mesothelioma Diagnosed?

Diagnosis and staging involve two different questions:

1. Is the disease pleural mesothelioma?
2. How far has it spread?

When antineoplastic treatment is planned, ASCO strongly recommends adequate tissue sampling, typically through thoracoscopic biopsy when feasible, because histologic subtype can materially affect treatment selection. Our diagnosis guide and tests and biopsy guide cover this process in more detail.

Pleural Fluid Evaluation

If symptomatic pleural effusion is present, ASCO recommends initial thoracentesis with cytologic examination as part of the assessment.

Thoracentesis can serve two purposes:

• obtain pleural fluid for evaluation;
• relieve breathlessness caused by fluid accumulation.

However, treatment planning often requires sufficient tissue to confirm histology and conduct further pathological studies.

Biopsy and Histology

A biopsy can establish the diagnosis and determine histologic subtype.

The major categories include:

• epithelioid;
• biphasic;
• sarcomatoid.

Histology is important because treatment outcomes and preferred systemic approaches differ among these groups.

Contrast-Enhanced CT

ASCO recommends CT of the chest and upper abdomen with IV contrast as the initial staging examination for pleural mesothelioma.

CT helps evaluate:

• pleural disease extent;
• chest-wall and mediastinal structures;
• regional lymph nodes;
• pleural fluid;
• suspicious disease outside the primary hemithorax.

If chest/upper-abdominal CT or PET/CT identifies abnormalities suspicious for abdominal metastatic disease, ASCO recommends further dedicated abdominal imaging when appropriate. Our imaging tests guide covers CT, PET, and MRI in more detail.

FDG PET/CT

ASCO recommends FDG PET/CT for initial staging, although it may be omitted in people who are not being considered for definitive surgical resection.

PET/CT can help identify disease that was not obvious on conventional imaging and can change the estimated extent of cancer.

An abnormal PET finding does not automatically confirm metastatic disease. The need for additional tissue confirmation depends on whether the result would alter management.

MRI

MRI with contrast can be used selectively when more detail is needed regarding structures such as the:

• diaphragm;
• chest wall;
• mediastinum.

How Is Stage 4 Mesothelioma Treated?

Treatment of Stage IV pleural mesothelioma generally focuses on systemic therapy, symptom management, and supportive care.

No single regimen is appropriate for all patients.

Treatment decisions can depend on:

• epithelioid versus nonepithelioid histology;
• performance status;
• heart, lung and kidney function;
• autoimmune disease or other contraindications to immunotherapy;
• previous treatment;
• disease burden;
• symptoms;
• treatment goals;
• patient preferences.

ASCO recommends systemic therapy for eligible pleural mesothelioma patients, as it can improve survival and quality of life. Our treatment guide covers these approaches across all stages.

Immunotherapy for Stage 4 Mesothelioma

Nivolumab Plus Ipilimumab — Nivolumab plus ipilimumab is an established first-line systemic treatment option for newly diagnosed pleural mesothelioma. The FDA-approved indication is specifically first-line treatment of adults with unresectable malignant pleural mesothelioma. ASCO recommends nivolumab plus ipilimumab as a first-line systemic option and gives it particular importance in patients with nonepithelioid disease.

In CheckMate 743, nivolumab plus ipilimumab improved overall survival compared with platinum-pemetrexed chemotherapy in previously untreated unresectable pleural mesothelioma. The difference was especially marked in the nonepithelioid subgroup, which historically responds poorly to chemotherapy.

Treatment choice remains individualized, as immune checkpoint inhibitors can cause significant immune-related toxicities and may not be suitable for all patients.

Pembrolizumab Plus Platinum-Pemetrexed — A second contemporary first-line approach combines pembrolizumab + pemetrexed + platinum chemotherapy. In September 2024, the FDA approved this combination for first-line treatment of adults with unresectable advanced or metastatic malignant pleural mesothelioma.

Approval was based on KEYNOTE-483. The trial showed a statistically significant overall-survival improvement for pembrolizumab plus chemotherapy compared with chemotherapy alone in patients with unresectable advanced or metastatic disease.

ASCO also identifies this chemoimmunotherapy regimen as a first-line option for newly diagnosed pleural mesothelioma across epithelioid and nonepithelioid histologies.

Stage IV status alone does not determine whether pembrolizumab-based chemoimmunotherapy or nivolumab/ipilimumab is preferable. The decision should be individualized.

Chemotherapy for Stage 4 Mesothelioma

Platinum-based chemotherapy with pemetrexed remains an established systemic treatment option, particularly for patients with epithelioid histology.

Common platinum options include:

• cisplatin;
• carboplatin when cisplatin is not appropriate.

ASCO states that carboplatin may be substituted for cisplatin in patients unable to tolerate cisplatin.

Pemetrexed + Platinum ± Bevacizumab — For patients with epithelioid histology, ASCO states that pemetrexed plus platinum-based chemotherapy, with or without bevacizumab in appropriately selected patients, may be offered as a first-line systemic treatment option. Bevacizumab is not suitable for all patients. Cardiovascular disease, uncontrolled hypertension, bleeding or clotting risk, performance status, age, and other clinical factors must be considered.

Nonepithelioid Disease — For previously untreated nonepithelioid pleural mesothelioma, current ASCO guidance states that chemotherapy alone generally should not be offered unless there is a medical contraindication to immunotherapy. Accurate histology identification is essential before selecting systemic treatment.

Treatment After Disease Progression

Treatment may continue after the initial regimen is no longer effective.

ASCO lists several potential later-line approaches depending on what treatment a patient has already received.

For example, patients previously treated with first-line immunotherapy may be considered for pemetrexed plus platinum-based chemotherapy, with or without bevacizumab in appropriate circumstances. In patients who have received both immunotherapy and pemetrexed-platinum chemotherapy, current ASCO guidance allows options such as vinorelbine or gemcitabine, with gemcitabine plus ramucirumab among the later-line approaches that may be considered.

The appropriate sequence depends heavily on:

• previous response;
• treatment toxicity;
• performance status;
• comorbidities;
• histology;
• available clinical trials.

Specialist oncology input is especially valuable in this context.

Is Surgery Used for Stage 4 Mesothelioma?

Maximal surgical cytoreduction is generally not used as definitive treatment for Stage IV pleural mesothelioma, as Stage IV is defined by distant metastatic disease.

ASCO recommends restricting maximal cytoreductive surgery to highly selected patients with favorable characteristics, such as early-stage T1–T3 N0 epithelioid disease, and no evidence of extrathoracic disease.

Stage IV M1 disease does not meet these criteria.

This does not mean that no procedure can ever be useful.

Procedures may still be performed to:

• manage pleural effusion;
• relieve symptoms;
• obtain diagnostic tissue;
• address selected complications.

These are different from maximal cytoreductive surgery intended to remove macroscopic pleural tumor.

Radiation Therapy in Stage 4 Mesothelioma

Radiation therapy can be beneficial for selected symptomatic sites, even if it cannot address all metastatic disease.

ASCO supports palliative radiation approaches depending on the target location and surrounding organs.

Possible goals can include:

• reducing pain from a localized tumor;
• controlling a symptomatic chest-wall mass;
• treating a painful metastatic site;
• improving symptoms from a focal area of progression.

Radiation decisions depend on anatomy, prior treatments, expected benefit, toxicity, and overall treatment goals.

Radiation should not be considered a cure for Stage IV disease.

Managing Pleural Effusion

Pleural effusion can significantly contribute to breathlessness and discomfort.

For patients who are not candidates for maximal cytoreductive surgery, ASCO states that options for symptomatic pleural effusion can include:

• tunneled pleural catheter placement;
• pleurodesis through a chest tube or thoracoscopy;
• selected thoracoscopic procedures.

The optimal approach depends on fluid recurrence rate, lung expansion, symptoms, overall health, and other clinical factors.

The primary goal is symptom control and improved quality of life, rather than cancer eradication.

Palliative Care for Stage 4 Mesothelioma

Palliative care is not the same as discontinuing cancer treatment.

Palliative care is specialized support aimed at improving quality of life by managing symptoms and addressing psychological, social, and other challenges associated with serious illness. It can be provided alongside cancer-directed therapy.

For someone with Stage 4 mesothelioma, palliative care may help with:

• breathlessness;
• pain;
• fatigue;
• appetite and nutrition concerns;
• treatment side effects;
• sleep;
• emotional distress;
• practical and caregiver needs.

Palliative care can begin early, well before end-of-life care is required.

Palliative Care vs Hospice Care

Palliative care and hospice care are distinct and not interchangeable.

Palliative care can be provided alongside disease-directed treatment and can begin at essentially any point in a serious illness.

Hospice care is focused on comfort when life-prolonging or curative treatment is no longer the goal.

In the United States, hospice eligibility typically requires an estimated prognosis of six months or less if the illness follows its expected course. This is a hospice eligibility guideline, not a definition of Stage 4 mesothelioma or a prediction for every patient.

A Stage 4 diagnosis alone does not require immediate hospice enrollment.

Clinical Trials for Stage 4 Mesothelioma

Clinical trials are especially important in rare cancers such as pleural mesothelioma.

Depending on eligibility and prior treatment, studies may investigate:

• new immunotherapy combinations;
• therapies for tumors progressing after checkpoint inhibitors;
• new chemotherapy combinations;
• biomarker-directed approaches;
• novel systemic treatments;
• symptom and supportive-care strategies.

NCI maintains mesothelioma treatment-trial resources and notes that clinical trials may test new therapies, new uses of existing therapies, and supportive or palliative approaches.

Participation should be considered alongside standard treatment options, potential benefits, uncertainties, eligibility criteria, and possible risks.

Why Histology Matters in Stage 4 Mesothelioma

Stage refers to anatomical extent, while histology describes the microscopic tumor type.

They answer different questions.

Epithelioid Mesothelioma

Epithelioid mesothelioma generally has a more favorable prognosis than nonepithelioid disease and offers several reasonable first-line systemic approaches, depending on the patient. ASCO recognizes nivolumab/ipilimumab, platinum-pemetrexed chemotherapy in appropriate patients, and pembrolizumab/platinum/pemetrexed chemoimmunotherapy as options within contemporary treatment planning.

Biphasic and Sarcomatoid Mesothelioma

Biphasic and sarcomatoid tumors are collectively considered nonepithelioid in many treatment discussions.

ASCO recommends nivolumab plus ipilimumab as the preferred first-line approach for previously untreated nonepithelioid disease when immunotherapy is not contraindicated.

This distinction is clinically important: two patients with the same Stage IV classification may receive different treatment recommendations based on their histology and medical circumstances.

Stage 4 Mesothelioma Prognosis

Stage IV pleural mesothelioma is advanced metastatic disease, and prognosis is generally less favorable than for disease diagnosed before distant metastasis.

However, stage is only one factor influencing prognosis.

The NCI identifies several factors that can influence mesothelioma outcome, including:

• stage;
• tumor extent;
• histology;
• age;
• performance status;
• overall health;
• heart and lung health;
• amount of pleural fluid;
• blood-count parameters;
• whether disease is newly diagnosed or recurrent.

Response to treatment also varies substantially between individuals.

For this reason, no population statistic can accurately predict how long one specific person will live. Our prognosis guide discusses these factors across all stages.

Stage 4 Mesothelioma Life Expectancy

There is no single medically reliable life-expectancy figure for every person with Stage 4 mesothelioma.

You may see websites claiming:

“Stage 4 life expectancy is X months.”

Such figures can be misleading, as they may combine:

• different staging editions;
• different histologic subtypes;
• patients treated in different eras;
• different performance-status groups;
• different systemic therapies;
• newly diagnosed and recurrent disease.

Version 9 changed pleural mesothelioma stage groupings, so older stage-specific literature should be interpreted carefully.

Individual prognosis should be discussed with the treating oncology team, based on the actual clinical situation rather than generic online statistics.

Stage 4 Mesothelioma Survival Rate

Current American Cancer Society data provide survival by SEER Summary Stage, not by AJCC Stage IV.

For pleural mesothelioma, the ACS currently reports a 5-year relative survival rate of 11% for SEER “distant” disease.

However, this statistic needs an important qualification:

SEER distant disease is not the same classification system as AJCC Version 9 Stage IV.

SEER uses:

• localized;
• regional;
• distant.

AJCC uses TNM categories and Stage I–IV groupings.

Therefore, the 11% figure should not be relabeled as “the Stage 4 survival rate.”

ACS notes that these statistics are based on patients diagnosed in earlier years and may not fully reflect newer treatments.

Can Stage 4 Mesothelioma Be Cured?

Stage IV pleural mesothelioma is generally not curable with current standard treatments.

Treatment is typically directed toward:

• controlling cancer;
• slowing progression;
• prolonging survival when possible;
• relieving symptoms;
• preserving function;
• maintaining quality of life.

Modern systemic treatments can provide meaningful disease control for some patients, but neither immunotherapy nor chemotherapy guarantees a cure.

ASCO recommends systemic therapy for appropriate patients, as it can improve survival and quality of life.

Is Stage 4 Mesothelioma Terminal?

Stage 4 is advanced metastatic cancer and is generally not curable, but “terminal” is not a treatment plan.

A Stage IV diagnosis does not automatically preclude cancer-directed therapy, clinical trials, symptom-directed radiation, pleural procedures, or specialist palliative care.

Some patients are eligible for first-line and subsequent systemic treatments, while others may require comfort-focused care due to medical conditions, cancer burden, or declining performance status.

ASCO notes that selected patients with poor performance status may be better served by limited palliative treatment or palliative care, with the decision individualized to their clinical condition.

Hospice is considered when care goals shift entirely to comfort and the patient meets eligibility criteria.

Why a Mesothelioma Specialist Matters

Stage IV treatment now involves more than a choice between “chemotherapy” and “no treatment.”

Current management may involve decisions among:

• nivolumab/ipilimumab;
• pembrolizumab/platinum/pemetrexed;
• platinum-pemetrexed-based treatment;
• selected use of bevacizumab;
• later-line systemic treatments;
• clinical trials;
• radiation;
• pleural procedures;
• palliative care.

ASCO guidelines emphasize individualized treatment based on histology, performance status, medical contraindications, and prior therapy.

Because pleural mesothelioma is rare, specialist pathology and multidisciplinary review are valuable. The NCI notes that a second opinion can help confirm diagnosis and treatment planning. Our find a specialist guide can help with that search.

What to Do After a Stage 4 Diagnosis

Questions worth discussing with the treating team include:

1. Was my disease staged using AJCC/UICC Version 9?
2. What finding established M1 disease?
3. Where has metastatic disease been identified?
4. Does any suspicious metastatic site need additional confirmation?
5. What is my histologic subtype?
6. Has a mesothelioma-experienced pathologist reviewed my pathology?
7. What is my performance status?
8. Am I a candidate for nivolumab plus ipilimumab?
9. Am I a candidate for pembrolizumab plus pemetrexed and platinum chemotherapy?
10. Would platinum-pemetrexed chemotherapy be appropriate for my histology?
11. Does bevacizumab have a role in my situation?
12. What treatment side effects are most relevant to my other medical conditions?
13. What would we use if the first treatment stops working?
14. Are there clinical trials appropriate for my treatment history?
15. Does my pleural effusion need drainage, pleurodesis, or a tunneled catheter?
16. Could radiation help with a specific painful or symptomatic site?
17. When should palliative care become part of my treatment team?
18. What symptoms should prompt an urgent call to my oncology team?
19. Would a second opinion at a mesothelioma center be useful?
20. What are the realistic goals of treatment in my individual case?

Our patient resources hub and financial assistance guide cover practical support options for patients and families.

Frequently Asked Questions

What is Stage 4 mesothelioma?

Under AJCC/UICC TNM Version 9, Stage IV diffuse pleural mesothelioma is Any T, Any N, M1. The defining feature is distant metastatic disease.

Does Stage 4 always mean the primary tumor is T4?

No. Stage IV can have any T category. M1 is what establishes Stage IV.

Is T4 mesothelioma always Stage 4?

No. T4 Any N M0 is Stage IIIB under Version 9. Stage IV requires M1.

Does spread to the opposite pleura always mean Stage 4?

Not automatically. TNM Version 9 lists direct extension to the contralateral pleura as a T4 feature. T4 with M0 is Stage IIIB. Separate distant metastatic involvement can instead represent M1 disease, so the pattern needs clinical interpretation.

Where can Stage 4 mesothelioma spread?

Examples include distant lymph nodes, bones, liver, peritoneum, the opposite lung or pleural region when metastatic, and other distant organs.

Is Stage 4 mesothelioma treatable?

Yes. Although Stage IV is generally not considered curable, systemic therapy and symptom-directed care can still be appropriate. ASCO recommends systemic treatment for eligible patients because it can improve survival and quality of life.

What immunotherapy is used for Stage 4 mesothelioma?

Nivolumab plus ipilimumab is an established first-line option for unresectable pleural mesothelioma. Pembrolizumab combined with pemetrexed and platinum chemotherapy is also FDA-approved as first-line therapy for unresectable advanced or metastatic malignant pleural mesothelioma.

Is immunotherapy better than chemotherapy?

There is no universal answer. Histology matters. ASCO particularly favors nivolumab/ipilimumab for previously untreated nonepithelioid disease, while several first-line options can be reasonable for epithelioid disease. Individual medical factors and treatment goals also matter.

Can Stage 4 mesothelioma be operated on?

Maximal surgical cytoreduction is generally not appropriate for Stage IV M1 disease because ASCO restricts this surgery to highly selected patients without extrathoracic disease and with favorable characteristics. Procedures can still be used for diagnosis or symptom relief.

Can radiation be used in Stage 4?

Yes, in selected situations. Palliative radiation can be used to treat specific symptomatic areas, such as a painful focal tumor site.

What is the Stage 4 mesothelioma survival rate?

There is no single current AJCC Version 9 Stage IV survival percentage that accurately predicts an individual outcome. ACS reports 11% 5-year relative survival for SEER distant pleural mesothelioma, but SEER distant and AJCC Stage IV are not identical classifications.

What is the life expectancy for Stage 4 mesothelioma?

There is no single reliable number for all patients. Prognosis varies with histology, age, performance status, overall health, disease burden, treatment, and treatment response.

Is Stage 4 mesothelioma terminal?

Stage IV is advanced metastatic disease and generally is not considered curable, but treatment may still be appropriate. Decisions about systemic therapy, clinical trials, palliative treatment or hospice depend on the person’s condition and treatment goals rather than the stage label alone.

Is palliative care the same as hospice?

No. Palliative care can be given alongside cancer-directed treatment. Hospice is focused on comfort when disease-directed curative or life-prolonging treatment is no longer the goal.

Should someone with Stage 4 mesothelioma get a second opinion?

A second opinion can be useful, particularly in a rare cancer where pathology, histology, and treatment sequencing can materially affect the plan. The NCI specifically notes that second opinions can help confirm diagnosis and treatment planning.

Medical References

1. American Joint Committee on Cancer. Diffuse Pleural Mesothelioma. AJCC Cancer Staging System, Version 9. American College of Surgeons; 2024.
2. NHS England / National Disease Registration Service. Pleural Mesothelioma — TNM 9th Edition Staging Guidance. Updated January 16, 2026.
3. American Cancer Society. Stages of Mesothelioma. Revised February 3, 2026.
4. Kindler HL, Ismaila N, Bazhenova L, et al. Treatment of Pleural Mesothelioma: ASCO Guideline Update. Journal of Clinical Oncology. 2025;43:1006–1038. doi:10.1200/JCO-24-02425.
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Mesothelioma: Pleural. Version 2.2026.
6. National Cancer Institute. Mesothelioma Diagnosis & Prognosis. Updated May 16, 2025.
7. National Cancer Institute. Treatment for Mesothelioma. Updated May 16, 2025.
8. National Cancer Institute. Malignant Mesothelioma Treatment (PDQ®) — Health Professional Version.
9. U.S. Food and Drug Administration. Nivolumab plus ipilimumab approval for first-line treatment of adults with unresectable malignant pleural mesothelioma.
10. U.S. Food and Drug Administration. FDA Approves Pembrolizumab With Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma. September 17, 2024.
11. American Cancer Society. Survival Rates for Pleural Mesothelioma. Revised February 3, 2026.
12. National Cancer Institute. Palliative Care in Cancer.

Editorial and Medical Review Information